Phathom Pharmaceuticals vs Syndax Pharmaceuticals
Phathom Pharmaceuticals and Syndax Pharmaceuticals are similar in size: $175m and $172m of revenue in their latest fiscal years. Syndax Pharmaceuticals grew faster (627.8% against 216.9%). Phathom Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -126.3% against -165.6%.
| Latest fiscal year | Phathom PharmaceuticalsPHAT, 2025 | Syndax PharmaceuticalsSNDX, 2025 |
|---|---|---|
| Revenue | $175m | $172m |
| Revenue growth | 216.9% | 627.8% |
| Net income | −$221m | −$285m |
| Operating margin | -91.4% | -158.4% |
| Net margin | -126.3% | -165.6% |
| Return on equity | — | -161.8% |
| Free cash flow | −$167m | −$323m |
| Cash | $130m | $135m |
| Total debt | $209m | $350m |
| Debt to equity | — | 541.5% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 371 | 298 |
| Market value | $449m | $1.29bn |
| Price vs our value range | — | — |
| Moat score | — | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 1 sales | 0 buys, 10 sales |